Details for New Drug Application (NDA): 206099
✉ Email this page to a colleague
NDA 206099 describes ONZETRA XSAIL, which is a drug marketed by Currax and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the ONZETRA XSAIL profile page.
The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 206099
| Tradename: | ONZETRA XSAIL |
| Applicant: | Currax |
| Ingredient: | sumatriptan succinate |
| Patents: | 15 |
Pharmacology for NDA: 206099
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Suppliers and Packaging for NDA: 206099
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099 | NDA | Currax Pharmaceuticals LLC | 42847-311 | 42847-311-08 | 8 POUCH in 1 CARTON (42847-311-08) / 2 CAPSULE in 1 POUCH |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;NASAL | Strength | EQ 11MG BASE | ||||
| Approval Date: | Jan 27, 2016 | TE: | RLD: | Yes | |||||
| Patent: | 10,076,614 | Patent Expiration: | Oct 20, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 10,076,615 | Patent Expiration: | Jul 30, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE | ||||||||
| Patent: | 10,076,615 | Patent Expiration: | Jul 30, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY | ||||||||
Expired US Patents for NDA 206099
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 8,555,877 | ⤷ Get Started Free |
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 6,715,485 | ⤷ Get Started Free |
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 9,108,015 | ⤷ Get Started Free |
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 8,590,530 | ⤷ Get Started Free |
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 8,327,844 | ⤷ Get Started Free |
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | 8,047,202 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
